Five litigation signals from September 8–14: AI fair use, dataset scrutiny, TikTok safety, and pharma monopolies
A decision-ready intelligence briefing on five major AI, tech-platform, and pharma litigation developments, covering fair-use pretraining battles, dataset transparency, child safety deception, and drug exclusivity.
The September 8–14, 2026 window delivered substantive motions and dispositive rulings across foundation-model copyright, consumer protection on algorithmic platforms, and pharmaceutical market competition. In Manhattan federal court, publishers and generative AI developers filed cross-motions for summary judgment that force an early reckoning on whether language-model pretraining qualifies as fair use or unlawful market dilution. In California, federal scrutiny focused on the completeness of AI training dataset disclosures. State enforcement yielded a major deceptive-practices ruling against TikTok in Texas, while federal courts in Illinois and New Jersey advanced antitrust claims over multiple sclerosis treatments and blocked generic competition for a treatment-resistant depression therapy. The table provides the current procedural status, followed by detailed assessments of each matter.
Docket at a glance
| Sector | Parties | Docket | Current stage | Recent development | Next milestone |
|---|---|---|---|---|---|
| AI copyright | The New York Times, authors, and other publishers v. OpenAI Inc. and Microsoft Corp. | 1:25-md-03143 | Consolidated multidistrict copyright litigation | Cross-motions for summary judgment filed on the fair-use defense; reported September 8, 2026. 1 | Oral argument on summary judgment; date not public |
| AI training disclosures | Copyright plaintiffs including Entrepreneur Media Inc. v. Meta Platforms Inc. | not public | Pending copyright litigation in the Northern District of California | Judge Vince Chhabria questioned Meta's disclosure of nine magazine issues during a September 9, 2026 hearing. 2 | Order on scope of training-data production; date not public |
| Platform consumer protection | State of Texas v. TikTok Inc. and ByteDance Ltd. | not public | State enforcement action in Texas state court | State judge ruled on September 10, 2026, that TikTok violated state deceptive-trade law regarding restricted mode and child safety. 34 | Damages and civil penalty proceedings; date not public |
| Pharma antitrust | Walgreens Co. and The Kroger Co. v. Biogen Inc. | not public | Antitrust litigation in the Northern District of Illinois | District judge refused to dismiss pharmacy monopolization claims on September 8, 2026. 5 | Answer and formal discovery schedule; date not public |
| Pharma patent | Janssen Pharmaceuticals Inc. v. Sandoz International GmbH | not public | Hatch-Waxman patent litigation in the District of New Jersey | District judge Karen M. Williams ruled on September 9, 2026, that Sandoz's proposed generic esketamine spray infringes Janssen patents. 6 | Sandoz appeal to the Federal Circuit; deadline within 30 days |
AI
In re OpenAI Inc. Copyright Infringement Litigation: fair use meets market dilution
Parties: The New York Times Co., non-fiction authors, novelists including John Grisham and George R.R. Martin, and news organizations v. OpenAI Inc., OpenAI OpCo LLC, and Microsoft Corp.
Docket number:
1:25-md-03143, U.S. District Court for the Southern District of New York. Assigned to U.S. District Judge Sidney Stein. 1Claims: Plaintiffs allege direct and contributory copyright infringement, asserting that OpenAI and Microsoft copied millions of copyrighted news articles and books without license or compensation to train GPT models. OpenAI and Microsoft argue that ingestion of expressive text during pretraining extracts unprotectable statistical relationships rather than expressive content, qualifying as fair use. Authors counter that generative AI systems dilute the commercial market for human creative expression, while news publishers assert that synthetic summaries displace website readership and direct subscription revenue. 1
Current stage: Consolidated multidistrict litigation undergoing dispositive fair-use motions.
Recent development and event date: The parties filed cross-motions for summary judgment addressing the core fair-use defense on September 4, 2026, reported by Reuters on September 8, 2026. 1
Business impact: A merits determination in this consolidated proceeding will directly influence commercial licensing valuation across the foundation-model ecosystem. If the court rules that large-scale model pretraining requires explicit licenses for copyrighted text, developers face substantial statutory damages and mandatory licensing agreements. A defense win would formalize transformative fair use as a recognized standard for model pretraining across the Second Circuit.
Precedent value: This proceeding presents the first consolidated multidistrict test of fair use in foundation-model training since earlier decisions in the Northern District of California reached contrasting conclusions regarding market dilution and pirated shadow datasets. Judge Stein's evaluation of whether market substitution occurs at the pretraining stage or the output stage will establish authoritative guidance for pending AI copyright matters nationwide.
Next milestone: Scheduling of oral arguments on the cross-motions for summary judgment; date not public.
Meta Platforms AI training litigation: court questions narrow dataset disclosures
Parties: Putative copyright classes and publisher plaintiffs including Entrepreneur Media Inc. v. Meta Platforms Inc.
Docket number:
not public, U.S. District Court for the Northern District of California. Assigned to U.S. District Judge Vince Chhabria. 2Claims: Plaintiffs allege that Meta copied extensive print catalogues, periodicals, and literary works to train its Llama family of language models. During discovery, plaintiffs challenged Meta's formal disclosures regarding the specific magazine and serial publications included in its training corpora. Meta contended that its ingestion of periodicals was limited to nine specific magazine issues across a 17-year timeframe. 2
Current stage: Fact discovery and disputed motions to compel training dataset logs.
Recent development and event date: At a federal hearing on September 9, 2026, Judge Chhabria expressed skepticism regarding Meta's discovery assertions, characterizing the claim that an enterprise language model utilized only nine magazine issues over nearly two decades as improbable and directing further scrutiny into Meta's dataset logs. 2
Business impact: Technology companies deploying proprietary AI models face expanding discovery obligations to document and preserve pretraining datasets. Restrictive or curated disclosures risk judicial sanctions, adverse evidentiary inferences, and court orders compelling the production of comprehensive web-crawl logs and raw repository archives.
Precedent value: The proceeding demonstrates that courts will scrutinize developer assertions concerning the boundaries of their training corpora rather than accepting isolated sample disclosures. This sharpens discovery standards in AI infringement litigation, preventing defendants from limiting discovery to narrow subsets of ingested materials.
Next milestone: Formal written order regarding supplemental dataset production; date not public.
Tech
State of Texas v. TikTok: deceptive trade ruling targets child safety claims
Parties: The State of Texas (Office of the Attorney General) v. TikTok Inc. and ByteDance Ltd.
Claims: The State of Texas sued TikTok and parent company ByteDance under the Texas Deceptive Trade Practices-Consumer Protection Act, alleging that the platform misrepresented the effectiveness of parental controls and its "restricted mode" feature while continuing to serve inappropriate material to teenage accounts. TikTok asserted that its community guidelines and filtering tools comply with commercial standards and that state-level speech restrictions face federal preemption barriers. 34
Current stage: Liability determination entered in favor of the state; remedies and penalties pending.
Recent development and event date: A Texas state court judge ruled on Thursday, September 10, 2026 (reported September 11, 2026), that TikTok violated Texas consumer protection law by misleading parents and users about its content moderation practices and the protective capabilities of its restricted mode. 34
Business impact: Social media networks and content distribution platforms operating in the United States face immediate regulatory exposure under state consumer protection statutes. Companies marketing parental controls or algorithmic safeguards must ensure their operational filtering matches external promotional claims to avoid civil penalties and structural compliance mandates.
Precedent value: The decision confirms that state attorneys general can pursue platform operators for consumer fraud based on promotional statements about safety features without being barred by Section 230 of the Communications Decency Act. By framing the violation as deceptive marketing rather than publisher liability for third-party speech, the ruling creates a repeatable enforcement blueprint for state regulators nationwide.
Next milestone: Proceedings to determine civil penalties and potential injunctive mandates; date not public.
Pharma and biotech
Walgreens and Kroger v. Biogen: MS drug monopoly claims survive dismissal
Parties: Walgreens Co. and The Kroger Co. v. Biogen Inc.
Docket number:
not public, U.S. District Court for the Northern District of Illinois. 5Claims: Retail pharmacies Walgreens and Kroger allege that Biogen unlawfully preserved a monopoly over its blockbuster multiple sclerosis drug Tecfidera (dimethyl fumarate) by prosecuting an invalid patent (U.S. Patent No. 8,399,514) and using sham patent enforcement to delay affordable generic alternatives. Biogen moved to dismiss the complaint under Federal Rule of Civil Procedure 12(b)(6), arguing that the pharmacies failed to establish a direct causal injury and lacked antitrust standing. 5
Current stage: Motion to dismiss denied; case proceeding to formal discovery.
Recent development and event date: On September 8, 2026, an Illinois federal judge denied Biogen's motion to dismiss, holding that the retail pharmacies sufficiently pleaded that they suffered a concrete economic injury resulting from Biogen's exclusionary tactics and inflated wholesale pricing. 5
Business impact: Brand-name pharmaceutical manufacturers face ongoing antitrust exposure from retail chains and direct purchasers over patent thickets and lifecycle preservation strategies. Surviving the motion to dismiss exposes Biogen to extensive internal discovery regarding its patent prosecution history and generic settlement negotiations.
Precedent value: The decision solidifies direct-purchaser pharmacy standing to pursue Sherman Act Section 2 claims for overcharges stemming from patent lifecycle extensions, even following previous regulatory patent invalidations. It reinforces judicial scrutiny of late-listed formulation and dosage patents used to suppress generic entry.
Next milestone: Biogen's formal answer to the complaint and initial discovery scheduling; date not public.
Janssen Pharmaceuticals v. Sandoz: court blocks generic esketamine nasal spray
Parties: Janssen Pharmaceuticals Inc. (a subsidiary of Johnson & Johnson) v. Sandoz International GmbH and Alkem Laboratories Ltd.
Docket number:
not public, U.S. District Court for the District of New Jersey. Assigned to U.S. District Judge Karen M. Williams. Asserted patents include U.S. Patent Nos. 10,869,844, 11,173,134, 11,311,500, and 11,446,260. 6Claims: Janssen filed a patent infringement action under the Hatch-Waxman Act following Abbreviated New Drug Applications (ANDAs) by Sandoz and Alkem seeking regulatory approval to market generic versions of Spravato (esketamine hydrochloride nasal spray), an approved treatment for treatment-resistant depression. Sandoz asserted that Janssen's method-of-treatment and specialized nasal solution formulation patents were invalid for obviousness and not infringed by its proposed product labeling. 6
Current stage: Patent infringement judgment entered for the patent owner following district court review.
Recent development and event date: On September 9, 2026, Judge Karen M. Williams held that Sandoz's proposed generic nasal spray infringes Janssen's valid patents, rejecting generic invalidity defenses and barring commercial marketing until patent expiration. 6
Business impact: The ruling preserves Johnson & Johnson's market exclusivity over Spravato, shielding a revenue driver in its psychiatric portfolio from immediate generic erosion. Sandoz and competing generic filers must delay market entry or pursue a reversal before the Federal Circuit.
Precedent value: The judgment upholds method-of-use and formulation patent claims covering specific nasal administration protocols and aqueous stabilization for psychiatric compounds, affirming that targeted dosing regimens can sustain viable barriers against generic skinny-label attempts.
Next milestone: Sandoz notice of appeal to the U.S. Court of Appeals for the Federal Circuit; deadline within 30 days of judgment entry.
Cases to watch
- In re OpenAI Inc. Copyright Infringement Litigation: watch for the Southern District of New York's scheduling of oral arguments on fair use, which will determine whether foundation-model training faces Second Circuit licensing constraints.
- Meta Platforms AI training litigation: watch for Judge Chhabria's formal order detailing the required scope of historical magazine and periodical training-data disclosures.
- State of Texas v. TikTok: watch the subsequent remedies hearing in Texas state court for the assessment of statutory civil penalties and potential operational restrictions on the platform's restricted mode.
- Walgreens and Kroger v. Biogen: watch for Biogen's formal answer and initial discovery disclosures regarding internal patent prosecution decisions for Tecfidera.
- Janssen v. Sandoz: watch for Sandoz's formal notice of appeal to the Federal Circuit and whether the generic manufacturer seeks an expedited briefing schedule.
References
- 1
- 2
- 3
- 4
- 5
- 6
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.
Related content
More from this channel
- Six litigation signals from October 6–12: a quarter-billion-dollar publisher suit against OpenAI, four states against TP-Link, and a cross-border patent injunction
- Six litigation signals from September 29–October 5: the first appellate AI fair-use ruling, a rogue-agent suit against OpenAI, and a record gig-work settlement
- Six litigation signals from September 22–28: a record $5.7 billion haptic verdict, Anthropic's Pentagon loss, and a cleared Orange Book listing
- Six litigation signals from September 15–21: AI pacing antitrust, Google's ad tech remedy, and two pharma patent fights
- Six litigation signals from September 1–7: AI training, artist identity, trade secrets, and mifepristone
- Six litigation signals from August 24–31: Anthropic, Meta, Google, Asus, Luma, and Vertex
- Apple–OpenAI Discovery Fight, TikTok's $400M Deal, and a $56M Patent Verdict: Litigation Tracker — Week of August 18
- Kalshi's Washington Ban, Meta's Trial, and Lilly's Retatrutide Suits: Litigation Tracker - Week of August 11